Kavita Vinod Paul: Transforming Lives Through Comprehensive Care and Community Leadership
Kavita Vinod Paul, National Sales Head at Novo Nordisk, shared a post on LinkedIn:
“I had the opportunity to meet Dr. Maganti BSV Prasad and team, whose unwavering commitment has transformed the lives of thousands of individuals living with hemophilia, thalassemia, sickle cell disease, von Willebrand disease, and other inherited blood disorders.
As the driving force behind the Hemophilia Society, Vijayawada Chapter – Eluru, Dr. Prasad has built far more than a patient support organization – he has created a legacy of compassionate care, early diagnosis, quality diagnostics, patient education, genetic counselling, physiotherapy, psychosocial support, and community empowerment that has touched three generations of patients and families.
What inspired me even more was the Society’s commitment to nurturing future leaders. Under Dr. Prasad’s guidance, the organization has mentored and inspired:
- 1 MD Radiologist
- 4 MBBS students
- 3 IIT graduates
- 3 PhD scholars
- 2 Chartered Accountants
- 3 NIT graduates
- 2 IIIT graduates
- 100 and more IT professionals
- 30 and more professionals serving in Government Services
This extraordinary contribution demonstrates that patient organizations can create an impact far beyond healthcare – empowering individuals, building careers, and inspiring generations of professionals committed to giving back to society.
The Hemophilia Society, Vijayawada Chapter, in collaboration with the Indian Red Cross Society, Eluru District Branch, is a remarkable example of how vision, partnerships, and selfless leadership can improve access to comprehensive care while creating lasting social impact.
My sincere gratitude to Dr. Maganti BSV Prasad and the entire team for their warm hospitality and for reminding us that true leadership is measured not only by the lives we heal but also by the lives we inspire.
Thank you Singa Reddy for the opportunity!”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke